UTHRStock
Verdicts genuinely change. Free email alert the moment UTHR's does — no target price to set, unlike a price alert.
Near limit Ratio screen, 0 of 7 decided standards passing. AAOIFI, Dow Jones Islamic, FTSE Shariah, MSCI Islamic, MSCI Islamic M-Series, S&P Shariah, Usmani are within 3 points of their line. If they all crossed, the majority verdict would move from Not compliant to Compliant. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
UTHR is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →
How the status reached this point
Non-compliant · status tracked since Nov 17, 2026
No change to UTHR’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from our own screen, last on Nov 19, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $25.7B as of 2026-11-19.
Business activity: cleared (no excluded categories detected)
AAOIFI Fail 2 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 30.00% | Pass(30.0pp buffer) |
| Interest-bearing investments | 8.05% | 30.00% | Pass(21.9pp buffer) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
Usmani Fail 4 of 5 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Interest-bearing investments | 29.40% | 33.00% | Pass(3.6pp buffer) |
| Non-liquid assets | 65.65% | at least 20.00% | Pass(45.6pp above the floor) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
| Net liquid assets per share | $1.8B | under mkt cap $25.7B | Pass |
MSCI Fail 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 29.40% | 33.33% | Pass(3.9pp buffer) |
| Accounts receivable | 34.35% | 33.33% | Fail(1.0pp over) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
FTSE Fail 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 29.40% | 33.33% | Pass(3.9pp buffer) |
| Accounts receivable | 34.35% | 50.00% | Pass(15.6pp buffer) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
Dow Jones Islamic Market Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Cash + interest-bearing securities | 10.38% | 33.00% | Pass(22.6pp buffer) |
| Accounts receivable | 1.75% | 33.00% | Pass(31.2pp buffer) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
S&P Shariah Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.00% | Pass(33.0pp buffer) |
| Cash + interest-bearing securities | 11.85% | 49.00% | Pass(37.2pp buffer) |
| Accounts receivable | 2.00% | 49.00% | Pass(47.0pp buffer) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
MSCI M-Series Fail 3 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.00% | 33.33% | Pass(33.3pp buffer) |
| Cash + interest-bearing securities | 11.85% | 33.33% | Pass(21.5pp buffer) |
| Accounts receivable | 13.84% | 49.00% | Pass(35.2pp buffer) |
| Non-permissible income | 6.03% | 5.00% | Fail(1.0pp over) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from UTHR's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $3.2B | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $0 | 2026-09-30 | no debt tag reported in 3+ years (treated as $0) |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $2.1B | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, MarketableSecuritiesCurrent |
| Total assetsBalance sheet total | $7.0B | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $25.7B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $17.0B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $19.1B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $192.0M | 2025-12-31 | InvestmentIncomeInterest |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-04, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-02-25, period ended 2025-12-31. Screened 2026-11-19.
-
Total assets$7.0B
Assets· period ended 2026-09-30 · 10-Q filed 2026-11-04 -
Interest-bearing debt$0
no debt tag reported in 3+ years (treated as $0)· balance sheet as of 2026-09-30 · no filing link for this figure -
Cash and interest-bearing securities$2.1B
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents$1.2B · period ended 2026-09-30 · 10-Q filed 2026-11-04MarketableSecuritiesCurrent$879.0M · period ended 2026-09-30 · 10-Q filed 2026-11-04 -
Receivables$348.6M
AccountsReceivableNetCurrent· period ended 2026-09-30 · 10-Q filed 2026-11-04 -
Revenue$3.2B
RevenueFromContractWithCustomerExcludingAssessedTax· period ended 2025-12-31 · 10-K filed 2026-02-25 -
Interest income (non-permissible)$192.0M
InvestmentIncomeInterest· period ended 2025-12-31 · 10-K filed 2026-02-25 -
Market cap$25.7BMarket quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link
6 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.
What changed, and when
Verdict history for UTHR. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for UTHR has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 0 pass and 7 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-19.
Within 3 points of the line
- MSCI Islamic receivables ratio: 1.0pp over
- AAOIFI non permissible income ratio: 1.0pp over
- Usmani non permissible income ratio: 1.0pp over
- Dow Jones Islamic non permissible income ratio: 1.0pp over
- S&P Shariah non permissible income ratio: 1.0pp over
- MSCI Islamic non permissible income ratio: 1.0pp over
- MSCI Islamic M-Series non permissible income ratio: 1.0pp over
- FTSE Shariah non permissible income ratio: 1.0pp over
AAOIFI, Dow Jones Islamic, FTSE Shariah, MSCI Islamic, MSCI Islamic M-Series, S&P Shariah, Usmani are within 3 points of their line. If they all crossed, the majority verdict would move from Not compliant to Compliant.
The ratios that move with the share price
AAOIFI's debt ratio (0.0% against a 30% line) would only fail if the market cap fell by 100%, to $0.
AAOIFI's investments ratio (8.1% against a 30% line) would only fail if the market cap fell by 73%, to $6.9B.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Drug Manufacturers - Specialty & Generic listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| GALDYGalderma Group AG - ADR | $47.7B | — |
| HLNHaleon plc - ADR | $44.4B | — |
| NBIXNeurocrine Biosciences, Inc. | $15.9B | — |
| RDYDr. Reddy`s Laboratories Ltd. - ADR | $10.1B | — |
| ALKSAlkermes plc | $7.9B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold UTHR
24 of the 279 funds whose filed holdings we currently hold own UTHR shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns UTHR.
Shariah fundsUTHR fails our screen. These funds follow their own Shariah screens, which can reach a different answer from ours on the same company.
| Fund | UTHR in fund | Fund compliant by weight |
|---|---|---|
| MNZL Manzil Russell Halal USA Broad Market ETF | 0.08% | 88% |
Widely held U.S. index funds. If you own one, you own UTHR through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | UTHR in fund | Fund compliant by weight |
|---|---|---|
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND | 0.03% | 54% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.03% | 54% |
| SCHB Schwab U.S. Broad Market ETF | 0.03% | 53% |
| Fund | UTHR in fund | Fund compliant by weight |
|---|---|---|
| PINK Simplify Health Care ETF | 6.86% | 59% |
| IPFPX Poplar Forest Partners Fund | 4.85% | 19% |
| PBE Invesco Biotechnology & Genome ETF | 4.08% | 68% |
| BUL Pacer US Cash Cows Growth ETF | 2.81% | 70% |
| ASCE Allspring SMID Core ETF | 1.26% | 51% |
| MDYG State Street(R) SPDR(R) S & P 400(TM) Mid Cap Growth ETF | 1.22% | 63% |
| COWG Pacer US Large Cap Cash Cows Growth Leaders ETF | 0.92% | 76% |
| SPVZX PGIM Quant Solutions Mid-Cap Value Fund | 0.75% | 39% |
| JMEE JPMorgan Small & Mid Cap Enhanced Equity ETF | 0.65% | 42% |
| IVOO VANGUARD S&P MID-CAP 400 INDEX FUND | 0.61% | 47% |
10 more funds
| Fund | UTHR in fund | Fund compliant by weight |
|---|---|---|
| IPMSX VOYA INDEX PLUS MIDCAP PORTFOLIO | 0.44% | 47% |
| IWS iShares Russell Mid-Cap Value ETF | 0.22% | 36% |
| CVMC Calvert US Mid-Cap Core Responsible Index ETF | 0.22% | 42% |
| DFVX Dimensional US Large Cap Vector ETF | 0.13% | 44% |
| QUS State Street(R) SPDR(R) MSCI USA StrategicFactors(SM) ETF | 0.12% | 55% |
| SCHV Schwab U.S. Large-Cap Value ETF | 0.07% | 48% |
| IWD iShares Russell 1000 Value ETF | 0.06% | 41% |
| VONV VANGUARD RUSSELL 1000 VALUE INDEX FUND | 0.06% | 41% |
| TIQRX Nuveen Equity Index Fund | 0.03% | 51% |
| SFY SoFi Select 500 ETF | 0.02% | 61% |
Sorted by UTHR’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names UTHR once, so a bond is not counted as the shares; 1 more fund name UTHR in a way we cannot separate from its bonds, and is not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Peter Brown | Renaissance Technologies | $908M | 1.2% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $673M | 0.1% | 2026-09-30 |
| Baillie Gifford | Baillie Gifford & Co | $205M | 0.2% | 2026-09-30 |
| Israel Englander | Millennium Management | $175M | 0.1% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $96M | 0.1% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $68M | 0.3% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $48M | 0.1% | 2026-09-30 |
| Ken Fisher | Fisher Asset Management | $21M | 0.0% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $4M | 0.0% | 2026-09-30 |
| John Hussman | Hussman Strategic Advisors | $3M | 0.7% | 2026-09-30 |
| Charles Brandes | Brandes Investment Partners | $3M | 0.0% | 2026-09-30 |
| Jeremy Grantham | GMO | $2M | 0.0% | 2026-09-30 |
| Lee Ainslie | Maverick Capital | $1M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 43.60 | NEUTRAL |
| Stochastic %K (14) | 7.73 | BUY |
| CCI (20) | -185.59 | BUY |
| Williams %R (14) | -92.27 | BUY |
| MACD (12,26,9) | -4.85 | SELL |
| ROC (10) | -1.17 | SELL |
| Momentum (10) | -6.62 | SELL |
| EMA (10) | 580.50 | SELL |
| SMA (10) | 582.16 | SELL |
| EMA (20) | 578.21 | SELL |
| SMA (20) | 587.18 | SELL |
| EMA (30) | 571.55 | SELL |
| SMA (30) | 574.87 | SELL |
| EMA (50) | 560.06 | SELL |
| SMA (50) | 548.85 | BUY |
| EMA (100) | 546.55 | BUY |
| SMA (100) | 536.06 | BUY |
| EMA (200) | 535.40 | BUY |
| SMA (200) | 539.47 | BUY |
About UTHR
Healthcare · Drug Manufacturers - Specialty & Generic
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Background via Yahoo Finance — informational, not part of the verdict.
No real edge — avoid
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 44 |
| ⏰ 4H | RANGING | 39 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.